How Does VEGF Work? Mechanism of Action, Per the Research

Vascular endothelial growth factor (VEGF) is not a single molecule but a family of secreted glycoproteins, VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor, that signal mainly to endothelial cells lining blood and lymphatic vessels. A 2025 review in Signal Transduction and Targeted Therapy described VEGF signalling as a central regulator of vascular development, tissue homeostasis and multiple disease states, tracing the pathway from molecular mechanism through to therapeutic targeting (PMID 40383803). A 2016 review in Nature Reviews Molecular Cell Biology focused specifically on how endothelial VEGF receptor signalling is generated and then regulated inside the cell (PMID 27461391). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, nothing here describes a protocol, product or course of action.

Receptor Targets: Where VEGF Binds

VEGF ligands act on three related receptor tyrosine kinases plus a set of non-kinase co-receptors. Ligand binding brings two receptor molecules together, triggers trans-autophosphorylation of tyrosine residues in the intracellular domain, and creates docking sites for adaptor proteins, the canonical receptor tyrosine kinase sequence described in the 2016 endothelial signalling review (PMID 27461391).

Established Signalling: What Happens After the Receptor Dimerises

The best-characterised part of the mechanism sits downstream of VEGFR-2. Phosphorylated tyrosines recruit signalling proteins that branch into several parallel cascades, each mapped onto a different endothelial behaviour in the reviews below.

PLCγ-PKC-ERK: proliferation

A 2009 methods review of angiogenic signalling pathways described phospholipase C-gamma recruitment to the activated receptor, protein kinase C activation and downstream MAP kinase/ERK signalling as a route to endothelial cell proliferation and gene transcription (PMID 19301662). A 2008 review of the mechanisms of angiogenesis placed the same cascade within the broader programme of new vessel formation, alongside matrix degradation and endothelial migration (PMID 18707583).

PI3K-Akt-eNOS: survival, nitric oxide and permeability

Researchers describing endothelial VEGF receptor signalling have reported a phosphoinositide 3-kinase/Akt arm that supports endothelial survival and activates endothelial nitric oxide synthase, connecting receptor activation to vasodilation and to increased vascular permeability (PMID 27461391). The 2025 pathway review likewise presented permeability as a core, physiologically regulated output of VEGF signalling rather than an incidental side effect (PMID 40383803).

Src, junctions and the endothelial barrier

Src-family kinase signalling downstream of VEGFR-2 has been described as acting on VE-cadherin and adherens junctions, loosening cell-cell contacts so that endothelial cells can migrate and so that solutes can cross the barrier (PMID 27461391). The same review emphasised that junctional proteins are not only targets of the pathway but also feed back on receptor activity.

Receptor trafficking as a control layer

One of the clearer mechanistic refinements of the last two decades is that where the receptor is matters as much as whether it is bound. The 2016 review set out endocytosis, ubiquitination, phosphatase activity and co-receptor availability as regulators that determine the amplitude and duration of VEGF receptor signalling (PMID 27461391). A 2010 Nature study in mice and cultured cells reported that ephrin-B2 controls VEGFR-2 and VEGFR-3 internalisation and that this step was required for VEGF-induced angiogenesis and lymphangiogenesis (PMID 20445537), animal and in-vitro work, not a human finding.

Upstream Control: Why VEGF Is Released

VEGF expression is classically described as oxygen-sensitive: hypoxic tissue increases VEGF transcription, which recruits vessels toward the under-perfused area. The 2008 review of angiogenesis mechanisms laid out this hypoxia-driven loop alongside the balance of pro- and anti-angiogenic factors that determines whether new vessels actually form (PMID 18707583). A 2011 review on the evolution of angiogenesis placed the VEGF system in comparative context, describing how vascular signalling programmes arose and were conserved across species (PMID 21732276).

Downstream Physiology

Sprouting angiogenesis

At the tissue level, the reviews describe VEGF gradients selecting leading "tip" endothelial cells that extend filopodia toward the signal while trailing "stalk" cells proliferate to form the new vessel lumen, with basement-membrane breakdown and pericyte recruitment completing the sequence (PMID 18707583). The 2009 signalling review mapped the same process onto the intracellular cascades described above (PMID 19301662).

Lymphangiogenesis

Lymphatic vessel growth is handled largely through VEGFR-3; the 2010 mouse study reported that disrupting ephrin-B2-dependent receptor internalisation impaired VEGF-induced lymphangiogenesis as well as blood-vessel angiogenesis (PMID 20445537).

Maintenance of existing vessels

VEGF is not only a growth signal. A 2019 review in JASN described continuous VEGF signalling as necessary for the integrity of the glomerular filtration barrier, where podocyte-derived VEGF supports the adjacent fenestrated endothelium (PMID 30642877). That maintenance role is a key reason why blocking the pathway produces predictable organ effects.

Proposed and Less-Settled Mechanisms

Several VEGF functions are actively researched but are better described as proposed than established.

• Neural signalling. A 2018 review in the International Journal of Molecular Sciences examined VEGF signalling in neurological disorders, discussing roles beyond blood vessels including effects on neural tissue and the blood-brain barrier (PMID 29342116).
• Cancer stem cell biology. A 2019 review described VEGF/neuropilin signalling as an autocrine axis of interest in cancer stem cells, distinct from the classical endothelial-only model (PMID 30678134).
• Pathway crosstalk in tumours. A 2021 Journal of Thoracic Oncology review set out the biological rationale for dual EGFR-VEGF pathway inhibition in EGFR-mutant non-small-cell lung cancer, based on described crosstalk between the two signalling systems (PMID 33096270).
• Muscle and ageing. A 2026 Nature Reviews Drug Discovery review surveyed treatment strategies under investigation for sarcopenia (PMID 42706321); any contribution of VEGF-driven capillary supply to muscle ageing remains a research question rather than a settled mechanism.

What Pathway Inhibition Reveals About Mechanism

Much of what is known about VEGF's ongoing physiological role comes from what happens when the pathway is blocked pharmacologically. The 2019 JASN review reported that therapeutic inhibition of VEGF signalling is associated with characteristic kidney effects, including proteinuria, hypertension and thrombotic microangiopathy, consistent with loss of the podocyte-endothelial VEGF signal (PMID 30642877). This page does not discuss doses, agents or regimens; it summarises mechanism only.

VEGF Pathway Inhibition: What Studies Report

Adverse-event information in the verified literature relates to drugs that block VEGF signalling in clinical oncology and ophthalmology settings, not to VEGF administration.

• The 2019 review reported nephrotoxicity, notably proteinuria and hypertension, as an associated consequence of therapeutic VEGF signalling inhibition (PMID 30642877).
• A 2020 review in Terapevticheskii Arkhiv likewise addressed the nephrotoxicity of anti-angiogenesis drugs as a recognised class issue (PMID 33346501).
• The 2021 oncology review discussed dual EGFR-VEGF inhibition as a strategy whose tolerability profile must be weighed alongside its biological rationale (PMID 33096270).

Established Versus Proposed: Summary Table

Limitations of the Evidence

Three caveats apply across this literature. First, a large share of the step-by-step mechanism was established in cultured endothelial cells and genetically modified mice, and the 2010 trafficking findings are explicitly animal and in-vitro work (PMID 20445537). Second, human clinical data in the verified set concern inhibition of the pathway rather than its stimulation, as in the nephrotoxicity reviews (PMID 33346501). Third, the pathway is context-dependent: the 2025 review stressed that VEGF outputs differ by tissue, receptor isoform and disease setting, which limits how far any single experimental result generalises (PMID 40383803). Nothing on this page describes an intervention, a quantity or an expected result in a person.

References

• Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives (Signal Transduction and Targeted Therapy, 2025)
• Mechanisms and regulation of endothelial VEGF receptor signalling (Nature Reviews Molecular Cell Biology, 2016)
• Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis (Nature, 2010)
• Angiogenic signalling pathways (Methods in Molecular Biology, 2009)
• Mechanisms of angiogenesis (Biochemistry. Biokhimiia, 2008)
• Evolution of angiogenesis (The International Journal of Developmental Biology, 2011)
• Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities (JASN, 2019)
• [Nephrotoxicity of anti-angiogenesis drugs] (Terapevticheskii Arkhiv, 2020)
• Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC (Journal of Thoracic Oncology, 2021)
• VEGF/Neuropilin Signaling in Cancer Stem Cells (International Journal of Molecular Sciences, 2019)
• VEGF Signaling in Neurological Disorders (International Journal of Molecular Sciences, 2018)
• Strengthening muscle for healthy ageing: innovative treatments for sarcopenia (Nature Reviews Drug Discovery, 2026)